
Bridge Biotherapeutics’ lung drug BBT-877 flops in phase 2 trial
Bridge Biotherapeutics' investigational treatment for idiopathic pulmonary fibrosis (IPF)—a rare, progressive lung disease that causes irreversible scarring—failed to beat placebo in a phase 2 study, the Korean biotech said Monday. The study tested …